Greenstone Biosciences

Greenstone Biosciences leverages a proprietary AI-driven platform combined with the world’s largest repository of patient-derived iPSC lines to accelerate drug discovery. The company has contributed to landmark studies identifying new therapeutic strategies for cardiac fibrosis and developed advanced tools for early cardiotoxicity detection. Their approach enables more precise modeling of human disease biology and pharmacogenomic variation, supporting both internal pipeline development and collaborations with academic partners worldwide. Recent preclinical results include successful reversal of cardiac fibrosis in engineered tissues and animal models by targeting SRC kinase pathways; their Genistein-based therapy has reached Phase 1/2 clinical evaluation in heart failure patients.